| Market Cap | 49.27M | P/E | - | EPS this Y | -8.30% | Ern Qtrly Grth | - |
| Income | -7.74M | Forward P/E | 21.38 | EPS next Y | 19.20% | 50D Avg Chg | -15.00% |
| Sales | 1.8M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -2.00% |
| Dividend | N/A | Price/Book | 4.56 | EPS next 5Y | - | 52W High Chg | -44.00% |
| Recommedations | 2.00 | Quick Ratio | 5.33 | Shares Outstanding | 29.48M | 52W Low Chg | 53.00% |
| Insider Own | 30.21% | ROA | -46.28% | Shares Float | 18.98M | Beta | 0.74 |
| Inst Own | 15.89% | ROE | -127.38% | Shares Shorted/Prior | 122K/150.90K | Price | 1.71 |
| Gross Margin | 50.01% | Profit Margin | - | Avg. Volume | 20,740 | Target Price | 6.00 |
| Oper. Margin | -528.50% | Earnings Date | Nov 6 | Volume | 12,930 | Change | -3.93% |
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| HC Wainwright & Co. | Buy | Jul 8, 24 |
| HC Wainwright & Co. | Buy | Nov 13, 23 |
| HC Wainwright & Co. | Buy | May 24, 23 |
| HC Wainwright & Co. | Buy | Feb 3, 23 |
| Dawson James | Neutral | Jul 18, 22 |
| HC Wainwright & Co. | Buy | Apr 5, 22 |
| HC Wainwright & Co. | Buy | Dec 17, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Francisco Trust under agreemen... | 10% Owner 10% Owner | Jul 27 | Sell | 4.65 | 175,000 | 813,750 | 3,548,528 | 09/20/22 |
| TCHELET RONEN | VP of Research and B.. VP of Research and Bus. Dvlpmt | Jul 07 | Option | 1.57 | 8,943 | 14,041 | 1,089 | 07/11/22 |
| TCHELET RONEN | VP of Research and B.. VP of Research and Bus. Dvlpmt | Jul 07 | Sell | 3.46 | 8,943 | 30,943 | 07/11/22 | |
| HERBST SETH | Director Director | Jan 28 | Option | 1.21 | 25,000 | 30,250 | 25,000 | 01/31/22 |
| EMALFARB MARK A | President and CEO President and CEO | Dec 21 | Option | 1.63 | 150,000 | 244,500 | 4,394,015 | 12/23/21 |
| EMALFARB MARK A | President and CEO President and CEO | Dec 21 | Sell | 4.18 | 90,902 | 379,970 | 4,244,015 | 12/23/21 |
| EMALFARB MARK A | President and CEO President and CEO | Jun 09 | Option | 1.67 | 100,000 | 167,000 | 4,334,917 | 06/09/21 |
| EMALFARB MARK A | President and CEO President and CEO | Jun 09 | Sell | 3.83 | 97,000 | 371,510 | 4,234,917 | 06/09/21 |
| Rawson Ping Wang | Chief Financial Offi.. Chief Financial Officer | Jun 04 | Buy | 3.73 | 11,000 | 41,030 | 9,650 | 06/04/21 |
| EMALFARB MARK A | President and CEO President and CEO | Jun 04 | Option | 1.67 | 400,000 | 668,000 | 4,331,917 | 06/04/21 |
| EMALFARB MARK A | President and CEO President and CEO | Jun 04 | Sell | 3.73 | 235,070 | 876,811 | 3,931,917 | 06/04/21 |